December 18, 2014 1:44 AM ET

Life Sciences Tools and Services

Company Overview of PsychoGenics Inc.

Company Overview

PsychoGenics Inc. provides preclinical contract research and drug discovery services for corporate and institutional clients. It offers standard and customized preclinical services; drug discovery services focused on psychiatric and neurodegenerative disorders, pain and inflammation, and spinal cord and traumatic brain injury; behavioral testing, electrophysiology, molecular biology, neuromorphology, neurogenesis, and microdialysis; and in-licensed transgenic mouse models that support research in areas, such as Huntington’s disease, autism spectrum disorders, psychosis/schizophrenia, Parkinson’s disease, spinal muscular atrophy, muscular dystrophy, and other muscle disorders. The company als...

765 Old Saw Mill River Road

Tarrytown, NY 10591

United States

Founded in 1999

Phone:

914-406-8000

Fax:

914-593-0645

Key Executives for PsychoGenics Inc.

Chief Executive Officer and President
Co-Founder and Director
Co-Founder and Director
Co-Founder
Senior Vice President of Behavioral Pharmacology
Compensation as of Fiscal Year 2014.

PsychoGenics Inc. Key Developments

PsychoGenics Receives License to the Cntnap2 Knockout Mouse Model from the Weizmann Institute

PsychoGenics Inc. announced that it has received a license to use the Cntnap2 knockout mouse from Yeda R&D Co. Ltd., the technology transfer company of the Weizmann Institute of Science. The CNTNAP2 gene encodes for Contactin Associated Protein 2 (Caspr2), a member of the neurexin family of cell recognition molecules. Mutations in this gene are associated with schizophrenia, autism, ADHD and language impairment. The Cntnap2 homozygous null mice were developed by Dr. Elior Peles. This model shows characteristics of Autism Spectrum Disorder (ASD) and ADHD such as deficits in a social test, hyperactivity in novel environments and changes in gait. Published reports describe reduced neonatal vocalizations, increased repetitive behavior and seizures, neuronal migration deficits with reduced interneuron number and asynchronous firing. In addition, pharmacological treatment with the antipsychotic risperidone improved repetitive behavior. Aspects of this phenotype were confirmed and expanded at PsychoGenics. This novel model of ASD promises to advance drug screening and development for ASD and associated disorders.

PsychoGenics Inc. and Sunovion Pharmaceuticals Inc. Expands Drug Discovery Partnership

PsychoGenics Inc. and Sunovion Pharmaceuticals Inc. announced that they have expanded the scope of their CNS drug discovery partnership and extended the agreement for another two years. The expanded agreement builds on the success of the partnership that has given rise to several CNS discovery programs. Sunovion and PsychoGenics will continue to advance existing discovery programs as well as screen new diverse compound libraries in vivo using PsychoGenics' proprietary SmartCube(R) System and broad preclinical capabilities, with the aim of identifying new therapies for CNS disorders.

Similar Private Companies By Industry

Company Name Region
Novasep, Inc. United States
Advanced Research Corporation United States
Cira Discovery Sciences, Inc. United States
LAMPIRE Biological Laboratories, Inc. United States
Algos Preclinical Services, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PsychoGenics Inc., please visit www.psychogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.